Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.76 USD | +0.61% | +1.99% | -34.09% |
Business Summary
Number of employees: 389
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Non-cash Royalties
73.3
%
| 45 | 46.2 % | 115 | 73.3 % | +153.00% |
License Fees and Milestones
16.0
%
| 5 | 5.1 % | 25 | 16.0 % | +400.00% |
Deferred Research and Development
7.8
%
| 10 | 9.7 % | 12 | 7.8 % | +28.06% |
Other
1.9
%
| 11 | 10.7 % | 3 | 1.9 % | -71.68% |
Research and Development
0.9
%
| 2 | 1.7 % | 1 | 0.9 % | -14.38% |
Clinical Product
0.1
%
| 1 | 0.8 % | 0 | 0.1 % | -84.78% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
98.1
%
| 88 | 89.3 % | 153 | 98.1 % | +75.22% |
Rest of World
1.9
%
| 11 | 10.7 % | 3 | 1.9 % | -71.68% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
Director of Finance/CFO | 58 | 95-12-31 | |
Craig Winter
CTO | Chief Tech/Sci/R&D Officer | - | - |
Steven O’Day
CTO | Chief Tech/Sci/R&D Officer | 63 | 20-12-31 |
Homa Yeganegi
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-19 |
Zack Armen
IRC | Investor Relations Contact | - | 22-11-30 |
Human Resources Officer | - | - | |
Eric Humes
PRN | Corporate Officer/Principal | - | 21-12-31 |
Alfred Dadson
PRN | Corporate Officer/Principal | - | 15-12-31 |
Robin Taylor
PRN | Corporate Officer/Principal | - | 23-07-19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
Director/Board Member | 66 | 16-05-16 | |
Susan Hirsch
BRD | Director/Board Member | 71 | 20-10-07 |
Brian Corvese
BRD | Director/Board Member | 67 | 07-03-07 |
Director/Board Member | 58 | 18-11-06 | |
Timothy Wright
BRD | Director/Board Member | 66 | 06-12-06 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 31,620 | 0 | 0 | 98.79 % |
Stock B | 1 | 20,999,261 | 20,744,282 ( 98.79 %) | 0 |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
MINK THERAPEUTICS, INC. 62.75% | 21,772,863 | 62.75% | 18,964,164 $ |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.09% | 225M | |
+40.47% | 54.04B | |
+45.77% | 41.96B | |
-1.86% | 41.92B | |
-7.20% | 28.35B | |
+11.53% | 26.35B | |
-21.71% | 19B | |
+4.87% | 13B | |
+29.12% | 12.28B | |
+25.41% | 12.19B |
- Stock Market
- Equities
- AGEN Stock
- Company Agenus Inc.